Human Resources
Lundbeck, Organon and AbbVie secure Great Place to Work certifications

Human Resources: Lundbeck and AbbVie announced that the companies have been certified a Great Place to Work in 2022.
Certification Nation Day on 17 May is a celebration of Certified great workplaces. For companies to carry the Certified label, current employees must verify that it’s a great place to work.
Lundbeck has been certified, the fifth year in a row, following an employee survey and benchmarking across a range of measures.
Lundbeck Australia Managing Director, Fredrik Kjaer, said “Being certified a Great Place to Work is welcome recognition of our efforts to build and maintain a company culture that exceeds Australian company benchmarks.
“It’s been a tough few years for employees across all industries due to the complexities of working in a COVID impacted world. I’m very proud that Lundbeck Australia employees have risen to the challenges, embracing new ways of working together and helping patients with mental and neurological illnesses. I’m particularly pleased that 98% of employees believe they make a difference working for Lundbeck Australia as this in line with our corporate values.
“Our work in brain health could not be more important and our long-term and unwavering focus on patients and our specialised therapy areas is, I know, what helps drive our unique culture. I look forward to more great results and continuing to be a Great Place to Work.”
Talent acquisition and retention: The current state of play in biopharma and medtech sectors
Lundbeck Australia Senior Medical Science Liaison, Jaymen Swift, said “Lundbeck remains a Great Place to Work for me as I’m able to take more than just pride in my work. I’m made to feel welcome, with my bosses and colleagues taking genuine interest in my personal life and goals. We’re given the means to grow, with our contributions being recognised and achievements celebrated as part of a team. Most importantly, I believe we are tangibly improving the wellbeing of patients across Australia and New Zealand, while also taking steps to improve diversity and inclusion in the pharmaceutical industry.”
AbbVie, whose Great Place to Work survey for 2022 is currently underway, will this year celebrate ten years being recognised as a Great Place to Work and is looking forward to being ranked on the Best Workplaces List in August.
In the last Great Place to Work survey 95% of AbbVie employees agreed AbbVie is a Great Place to Work, compared to the Australian workplace average of 55%. Reflecting the company’s commitment to equality, diversity and inclusion, 98% of employees said they feel they are treated fairly regardless of their gender.
In celebrating certification Chris Stemple, AbbVie VP and General Manager for ANZ, said “Being Great Place to Work-Certified is an incredible achievement for AbbVie Australia. This certification recognises our ongoing efforts to create a workplace culture and environment where our employees are empowered to bring their whole selves to work. With the values of inclusion and diversity at the core of our workplace, we’ve worked hard to create a safe space for our people that allows them to reach their full potential as part of our team.”
Sophie Althans, Director of HR Organon ANZ, said “We are so proud of our People First culture at Organon. We are less than one year old, and we work hard every day to support our founders across the spectrum in their business and personal endeavours, to allow them to reach their full potential and make a positive impact in the communities in which we live and work.
“Being Great Place to Work certified within our first 12 months speaks to the passion and commitment of our people to create a better and healthier every day for every woman.”
The Health Industry Hub news and professional development content are copyright protected and access is provided under individual user licenses. For more information, visit https://www.healthindustryhub.com.au/membership/ and T&Cs.
News & Trends - Pharmaceuticals

Clinicians shift stance, join calls for PBS subsidy of obesity and weight-loss medicines
Over a third of Australian adults live with obesity, and the National Obesity Strategy estimates the direct and indirect costs […]
MoreNews & Trends - Pharmaceuticals

Astellas secures new indication for prostate cancer drug
Astellas Xtandi (enzalutamide) is now TGA registered for a new indication for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with […]
MoreNews & Trends - MedTech & Diagnostics

Stakeholder calls intensify as government stalls on genetic discrimination ban
Calls have intensified for the federal government to honour its commitment to outlaw genetic discrimination in life insurance, as stakeholders […]
MoreNews & Trends - MedTech & Diagnostics

Pressure mounts to expand home-based therapies in kidney disease: World Kidney Day
As Australia marks World Kidney Day, the stark reality is that one in three adults is at risk of chronic […]
More